GT Biopharma Declares Prior Financials Unreliable, Details $28.7M Liability Restatement

summarizeSummary

GT Biopharma announced that its Q2 and Q3 2025 financial statements can no longer be relied upon due to an error in classifying "Greenshoe Rights" as a liability, leading to a significant restatement of liabilities and net loss.

check_boxKey Events

• Non-Reliance Declared

  The audit committee, in consultation with its independent auditor, concluded that the interim financial statements for Q2 and Q3 2025 can no longer be relied upon.

• Material Restatement of Liabilities

  An accounting error led to the reclassification of $28,736,000 in "Greenshoe Rights" from equity to a liability for the quarter ended June 30, 2025.

• Significant Impact on Equity and Net Loss

  The restatement caused total liabilities to increase from $2.3 million to $31.0 million and shifted total stockholders' equity from positive $2.8 million to a deficit of $25.8 million for Q2 2025. Net loss for Q2 2025 increased from $1.4 million to $30.1 million.

• No Cash Flow Impact

  The adjustments did not affect the company's reported net cash provided by or used in operating, investing, or financing activities for the affected periods.

auto_awesomeAnalysis

This 8-K provides critical details regarding the restatement of financial statements for Q2 and Q3 2025, which was broadly mentioned in the concurrently filed 10-K. The reclassification of $28.7 million in "Greenshoe Rights" from equity to liability for Q2 2025 is a massive adjustment relative to the company's financial position, causing total liabilities to surge and stockholders' equity to turn significantly negative. While the restatement did not impact cash flow, the declaration of non-reliance on previously issued financials signals severe internal control weaknesses and raises significant concerns about the company's financial reporting integrity and overall stability, especially given the existing going concern warning. Investors should be aware of the substantial negative impact on the balance sheet and historical profitability.